title: Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial.
abstract: OBJECTIVE
  To determine whether the addition of rifampin to a quinolone-based antibacterial prophylactic regimen in patients undergoing high-dose chemotherapy (HDC) with peripheral-blood stem-cell transplantation (PBSCT) decreases the incidence of neutropenia and fever, Gram-positive bacteremia, and infection-related morbidity.
  
  
  METHODS
  Patients with solid tumors undergoing HDC with PBSCT were randomized to receive prophylactic antibiotics with either ciprofloxacin 500 mg orally every 8 hours or the same ciprofloxacin regimen with rifampin 300 mg orally every 12 hours. Prophylaxis was started 48 hours before stem-cell reinfusion. Patients were monitored to document the occurrence of neutropenia and fever, incidence and cause of bacterial infection, time to onset and duration of fever, requirement for intravenous antimicrobials, and length of hospital admission.
  
  
  RESULTS
  Sixty-five patients were randomized to receive ciprofloxacin and 65 to receive ciprofloxacin plus rifampin, and from these groups, 62 and 61 were assessable, respectively. The proportion of patients who developed neutropenia and fever was 87% in the group treated with ciprofloxacin and 78% in the group treated with ciprofloxacin and rifampin (P =.25). Although there was a trend toward a reduction in the overall incidence of bacteremia (12 v 4 patients), and Gram-positive bacteremia (8 v 2 patients) with the addition of rifampin, none of these comparisons was statistically significant (P =.05 and P =.09, respectively).
  
  
  CONCLUSIONS
  The results of this study, which demonstrate that rifampin does not improve ciprofloxacin antibacterial prophylaxis in cancer patients undergoing HDC with PBSCT support but that it does increase the occurrence of undesirable side effects, do not support the routine use of rifampin in this setting.
authors.affiliation: Division of Medical Oncology, Microbiology, and Infectious Disease, Hospital Universitario "12 de Octubre," Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Gomez-Martin
authors.forename: C
authors.initials: C
authors.lastname: Solá
authors.forename: J
authors.initials: J
authors.lastname: Hornedo
authors.forename: S
authors.initials: S
authors.lastname: Perea
authors.forename: C
authors.initials: C
authors.lastname: Lumbreras
authors.forename: V
authors.initials: V
authors.lastname: Valentí
authors.forename: A
authors.initials: A
authors.lastname: Arcediano
authors.forename: M
authors.initials: M
authors.lastname: Rodriguez
authors.forename: R
authors.initials: R
authors.lastname: Salazar
authors.forename: H
authors.initials: H
authors.lastname: Cortés-Funes
authors.forename: M
authors.initials: M
authors.lastname: Hidalgo
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000517:prevention & control; D016908:Gram-Positive Bacterial Infections / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D011446:Prospective Studies; D012293:Rifampin / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D000970:Antineoplastic Agents; D002939:Ciprofloxacin; D012293:Rifampin